Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Trends Pharmacol Sci. 2016 Apr 6;37(6):463–484. doi: 10.1016/j.tips.2016.03.001

Figure 4.

Figure 4

Chemical structures of small molecules that suppress TGF-β1/ALK5 signaling. SJN2511 and SB431542 are selective ALK5 inhibitors. Losartan, a selective antagonist for AT1 can downregulate TGF-β/ALK5 signaling in both the periphery and the CNS. Abbreviations: ALK5, activin-like kinase 5; AT1, angiotensin II receptor type 1.